Safety and efficacy of two candidates are currently being assessed in investigator-initiated clinical trials. BRC is planning to commence enrollment for Phase 2 and 3 trials by mid 2026. MONTEREY, ...
SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and ...
Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NRSN) ("NeuroSense"), a ...
Program aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these products Detalimogene has already been manufactured ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological malignancies, today announced that the U.S. Food and Drug ...
PHILADELPHIA, March 18, 2026--(BUSINESS WIRE)--iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, ...
In 2026, the global regulatory framework for cell-based therapies continues to evolve, placing increased emphasis on robust CMC control strategies, comparability planning, and lifecycle management. As ...
Developing a new medication can cost over $1 billion, depending on the drug’s complexity and expenses accrued via unsuccessful studies. Considering these costs, an optimized regulatory process is ...
In this interview, News-Med talks to Tammy Newbold about the Global Harmonization of Regulatory CMC within Veterinary Medicine. Can you explain what global harmonization of regulatory CMC entails and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results